Cameron Turtle, Spyre Therapeutics CEO

Fresh from re­brand, Spyre Ther­a­peu­tics rais­es $180M as it steers TLA1 pro­gram to clin­ic

Spyre Ther­a­peu­tics is pulling in $180 mil­lion in a pri­vate place­ment just a cou­ple of weeks af­ter it re­brand­ed from Ae­glea Bio­Ther­a­peu­tics.

Spyre is sell­ing 6 mil­lion shares of its com­mon stock at $15 per share and 150,000 shares of its Se­ries B pre­ferred stock at $600 per share in a pri­vate place­ment. It’s ex­pect­ed to close around Dec. 11.

The pri­vate place­ment will ex­tend the biotech’s cash run­way in­to the sec­ond half of 2026 and sup­port de­vel­op­ment of its pipeline for gen­er­al cor­po­rate pur­pos­es and work­ing cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.